News and Trends 1 Sep 2022
Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose
Ensysce Biosciences, Inc., a clinical-stage biotech company, and Quotient Sciences, a drug development and manufacturing accelerator, are partnering to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences is currently using […]